The growing trend of obesity in adults and children has become a world-wide health threat. According to the most recent statistics (2017-2018) from the National Health and Nutrition Examination Survey (NHANES):
1 in 3 adults is overweight
1 in 6 children age 2-19 is overweight
2 in 5 adults are clinically obese
1 in 5 children age 2-19 is obese
While post-pandemic statistics on obesity are not yet available, we can expect to see greater percentages of the population diagnosed as overweight or obese.
To combat the growing trend of obesity and its associated metabolic comorbidities like hypertension and diabetes, researchers are looking for effective solutions to help people lose weight and reduce health risks that lead to premature death.
Weekly tirzepatide injections have recently been approved by the FDA to treat diabetic and obese patients, helping them to lose weight and achieve a better quality of life.
Tirzepatide — also marketed under the brand names Mounjaro and Zepbound — is a fairly new antidiabetic medication used for the treatment of type 2 diabetes and weight loss.. Administered weekly by subcutaneous injection, tirzepatide works by suppressing appetite and reducing total food intake.
The FDA has approved tirzepatide for chronic weight management in clinically obese adults, and in overweight adults with at least one metabolic condition such as high blood pressure, type 2 diabetes, dyslipidemia or heart disease.
Tirzepatide
+
DIET
+
exercise
+
Tirzepatide works by imitating GLP-1 and GIP — digestive hormones that the intestine secretes after a meal. The hormones trigger insulin secretion, helping your body to manage blood sugar levels. The drug also slows down the time it takes for food to leave the stomach, and signals the brain that you are full and satiated.
Tirzepatide is a fairly new antidiabetic medication used for the treatment of type 2 diabetes and weight loss.. Administered weekly by subcutaneous injection, tirzepatide works by suppressing appetite and reducing total food intake.
While some studies show promising results, it is too early to know if tirzepatide outperforms semaglutide for weight loss. Current available research has only studied and reported weight loss in people with type 2 diabetes, and no studies exist that match the two medications dose per dose.
Moderate side effects of tirzepatide include:
More severe side effects of tirzepatide include:
Abbasi, Jennifer. “FDA green-lights tirzepatide, marketed as Zepbound, for chronic weight management.” JAMA (2023).